Q1 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By William Blair (LIFE)

aTyr Pharma, Inc. (NASDAQ:LIFE) – William Blair upped their Q1 2018 earnings per share estimates for shares of aTyr Pharma in a report issued on Tuesday. William Blair analyst Y. Xu now anticipates that the biotechnology company will earn ($0.48) per share for the quarter, up from their prior forecast of ($0.53). William Blair also issued estimates for aTyr Pharma’s Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.48) EPS, Q4 2018 earnings at ($0.47) EPS and FY2018 earnings at ($1.91) EPS.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07.

A number of other brokerages also recently issued reports on LIFE. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.81.

aTyr Pharma (NASDAQ:LIFE) opened at $3.45 on Thursday. aTyr Pharma has a 1 year low of $2.30 and a 1 year high of $6.50. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17.

A number of hedge funds have recently modified their holdings of LIFE. Victory Capital Management Inc. bought a new stake in aTyr Pharma in the third quarter worth approximately $455,000. Artal Group S.A. bought a new stake in aTyr Pharma in the third quarter worth approximately $1,263,000. Finally, Dimensional Fund Advisors LP increased its holdings in aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares in the last quarter. Institutional investors and hedge funds own 58.30% of the company’s stock.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/08/q1-2018-earnings-forecast-for-atyr-pharma-inc-issued-by-william-blair-life.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply